文献速递咽喉与嗓音

自体脂肪间质血管组分注射治疗声带瘢痕的可行性:非随机对照试验

Feasibility of First Injection of Autologous Adipose Tissue-Derived Stromal Vascular Fraction in Human Scarred Vocal Folds: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2020-01-01

该前瞻性单臂非随机对照试验纳入8例声带瘢痕所致严重发音障碍患者,局部注射自体脂肪来源间质血管组分(ADSVF),随访12个月。结果显示治疗可行且耐受,所有患者嗓音障碍指数改善,平均改善40.1分,7例(88%)为应答者。结论需更大样本随机临床试验证实。

要点

  • ADSVF注射在声带瘢痕患者中可行且耐受,多数不良事件自行缓解。
  • 12个月时所有患者嗓音障碍指数改善,平均改善40.1分。
  • 7例(88%)达到最小临床重要差异(改善≥18分)。

核心结论

  • 自体ADSVF注射治疗声带瘢痕可行且可耐受,嗓音相关生活质量改善。

研究设计与样本

  • 前瞻性、开放标签、单臂、单中心非随机对照试验,纳入8例声带瘢痕相关严重发音障碍患者,随访12个月。

主要发现

  • 7例女性和1例男性,平均年龄44.6岁(SD 10.4)。
  • 脂肪抽吸和ADSVF注射相关不良事件多数自行缓解,1例需轻微处理引流局部瘀斑,1例抽脂部位出现轻微轮廓缺陷。
  • 12个月时所有患者嗓音障碍指数改善,平均改善40.1分(SD 21.5)。
  • 7例(88%)为应答者,定义为嗓音障碍指数改善≥18分(最小临床重要差异)。

关键数值与推荐

  • 应答者定义为嗓音障碍指数评分改善≥18分(最小临床重要差异)。

临床怎么用

  • 对于声带瘢痕所致严重发音障碍,ADSVF注射可能是一种可行的治疗选择,但需随机临床试验进一步验证。

局限性

  • 非随机、单臂、小样本(8例),结果需更大样本随机临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with scarred vocal folds, whether congenitally or after phonosurgery, often exhibit dysphonia that negatively affects daily life and is difficult to treat. The autologous adipose tissue-derived stromal vascular fraction (ADSVF) is a readily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. OBJECTIVE: To evaluate the feasibility and tolerability of local injections of autologous ADSVF in patients with scarred vocal folds. DESIGN, SETTING, AND PARTICIPANTS: CELLCORDES (Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction) is a prospective, open-label, single-arm, single-center, nonrandomized controlled trial with a 12-month follow-up and patient enrollment from April 1, 2016, to June 30, 2017. Eight patients with severe dysphonia attributable to vocal fold scarring associated with a congenital malformation or resulting from microsurgical sequelae (voice handicap index score >60 of 120) completed the study. Data analysis was performed from September 1, 2018, to January 1, 2019. INTERVENTIONS: Injection of ADSVF into 1 or 2 vocal folds. MAIN OUTCOMES AND MEASURES: The primary outcomes were feasibility and the number and severity of adverse events associated with ADSVF-based therapy. The secondary outcomes were changes in vocal assessment, videolaryngostroboscopy, self-evaluation of dysphonia, and quality of life at 1, 6, and 12 months after cell therapy. RESULTS: Seven women and 1 man (mean [SD] age, 44.6 [10.4] years) were enrolled in this study. Adverse events associated with liposuction and ADSVF injection occurred; most of them resolved spontaneously. One patient received minor treatment to drain local bruising, and another experienced a minor contour defect at the liposuction site. At 12 months, the voice handicap index score was improved in all patients, with a mean (SD) improvement from baseline of 40.1 (21.5) points. Seven patients (88%) were considered to be responders, defined as improvement by 18 points or more in the voice handicap index score (the minimum clinically important difference). CONCLUSIONS AND RELEVANCE: The findings suggest that autologous ADSVF injection in scarred vocal folds is feasible and tolerable. The findings require confirmation in a randomized clinical trial with a larger population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02622464.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Mattei A, Bertrand B, Jouve E, et al. Feasibility of First Injection of Autologous Adipose Tissue-Derived Stromal Vascular Fraction in Human Scarred Vocal Folds: A Nonrandomized Controlled Trial. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32053141. doi:10.1001/jamaoto.2019.4328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。